Kymera Therapeutic/KYMR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Kymera Therapeutic

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Ticker

KYMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Watertown, United States

Employees

186

KYMR Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-$2.50
EPS
2.25
Beta
-
Dividend rate
$2B
2.25
$45.31
$9.60
12
9.571
0.163
0.322
-20.86%
-26.35%
-22.67%
24.81
2.77
2.77
70.16%
12.87%
32.18%

What the Analysts think about KYMR

Analyst Ratings

Majority rating from 17 analysts.
Buy

KYMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-475.49% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-78.66%
Net income
-$49M
239.16%
Profit margin
-475.49%
1,489.74%

KYMR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.08%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.90
-$0.25
-$0.69
-
Expected
-$0.64
-$0.64
-$0.41
-$0.73
-$0.68
Surprise
5.24%
40.33%
-38.27%
-5.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kymera Therapeutic stock?

Kymera Therapeutic (KYMR) has a market cap of $2B as of June 24, 2024.

What is the P/E ratio for Kymera Therapeutic stock?

The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of June 24, 2024.

Does Kymera Therapeutic stock pay dividends?

No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of June 24, 2024.

When is the next Kymera Therapeutic dividend payment date?

Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Kymera Therapeutic?

Kymera Therapeutic (KYMR) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Kymera Therapeutic stock price target?

The target price for Kymera Therapeutic (KYMR) stock is $51.07, which is NaN% below the current price of $. This is an average based on projections from 14 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kymera Therapeutic stock

Buy or sell Kymera Therapeutic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing